ITMI20001603A0 - Formulazioni farmaceutiche solide orali a rilascio multifasico ph-dipendente - Google Patents

Formulazioni farmaceutiche solide orali a rilascio multifasico ph-dipendente

Info

Publication number
ITMI20001603A0
ITMI20001603A0 IT2000MI001603A ITMI20001603A ITMI20001603A0 IT MI20001603 A0 ITMI20001603 A0 IT MI20001603A0 IT 2000MI001603 A IT2000MI001603 A IT 2000MI001603A IT MI20001603 A ITMI20001603 A IT MI20001603A IT MI20001603 A0 ITMI20001603 A0 IT MI20001603A0
Authority
IT
Italy
Prior art keywords
pharmaceutical formulations
solid pharmaceutical
oral solid
multiphasic release
dependent
Prior art date
Application number
IT2000MI001603A
Other languages
English (en)
Inventor
Roberto Valducci
Original Assignee
Roberto Valducci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Valducci filed Critical Roberto Valducci
Publication of ITMI20001603A0 publication Critical patent/ITMI20001603A0/it
Priority to IT2000MI001603A priority Critical patent/IT1318625B1/it
Priority to US09/898,425 priority patent/US7022345B2/en
Priority to CA002352496A priority patent/CA2352496A1/en
Priority to DE60131703T priority patent/DE60131703T2/de
Priority to EP01116533A priority patent/EP1172100B1/en
Priority to AT01116533T priority patent/ATE380023T1/de
Priority to AU54324/01A priority patent/AU776099B2/en
Priority to JP2001213171A priority patent/JP2002080398A/ja
Publication of ITMI20001603A1 publication Critical patent/ITMI20001603A1/it
Application granted granted Critical
Publication of IT1318625B1 publication Critical patent/IT1318625B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT2000MI001603A 2000-07-14 2000-07-14 Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. IT1318625B1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT2000MI001603A IT1318625B1 (it) 2000-07-14 2000-07-14 Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US09/898,425 US7022345B2 (en) 2000-07-14 2001-07-03 Oral solid pharmaceutical formulations with pH-dependent multiphasic release
CA002352496A CA2352496A1 (en) 2000-07-14 2001-07-06 Oral solid pharmaceutical formulations with ph-dependent multiphasic release
EP01116533A EP1172100B1 (en) 2000-07-14 2001-07-09 Oral solid pharmaceutical formulations with ph-dependent multiphasic release
DE60131703T DE60131703T2 (de) 2000-07-14 2001-07-09 Orale feste pharmazeutische Zusammensetzungen mit pH-abhängiger Mehrphasen- Freisetzung
AT01116533T ATE380023T1 (de) 2000-07-14 2001-07-09 Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
AU54324/01A AU776099B2 (en) 2000-07-14 2001-07-11 Oral solid pharmaceutical formulations with ph-dependent multiphasic release
JP2001213171A JP2002080398A (ja) 2000-07-14 2001-07-13 ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001603A IT1318625B1 (it) 2000-07-14 2000-07-14 Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.

Publications (3)

Publication Number Publication Date
ITMI20001603A0 true ITMI20001603A0 (it) 2000-07-14
ITMI20001603A1 ITMI20001603A1 (it) 2002-01-14
IT1318625B1 IT1318625B1 (it) 2003-08-27

Family

ID=11445483

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2000MI001603A IT1318625B1 (it) 2000-07-14 2000-07-14 Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.

Country Status (8)

Country Link
US (1) US7022345B2 (it)
EP (1) EP1172100B1 (it)
JP (1) JP2002080398A (it)
AT (1) ATE380023T1 (it)
AU (1) AU776099B2 (it)
CA (1) CA2352496A1 (it)
DE (1) DE60131703T2 (it)
IT (1) IT1318625B1 (it)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DE60130270T2 (de) * 2001-10-15 2008-05-29 Ferring B.V. Verfahren zur herstellung einer pharmazeutischen zubereitung mit 5-aminosalicylsäure zur verwendung bei der behandlung von colitis ulcerosa und morbus crohn
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
BR0309093A (pt) * 2002-04-09 2005-02-09 Flamel Tech Sa Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
EP2143424A4 (en) * 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2255794A1 (en) * 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Enteric coating
HU228001B1 (en) 2010-07-27 2012-08-28 Peter Soldos Equipment for improving physical strength
HU230560B1 (hu) 2010-07-30 2016-12-28 Péter Hajnal pH-függő szakaszos és nyújtott hatóanyagleadású gyógyszerkészítmény
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
CN102784154B (zh) * 2012-09-01 2013-10-09 朱文军 一种美沙拉嗪肠溶片及其制备方法
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
JP6294457B2 (ja) * 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
EP3193845A1 (en) 2014-09-19 2017-07-26 The Procter and Gamble Company Pulsed release phenylephrine dosage forms
ES2919874T3 (es) * 2014-09-24 2022-07-28 Vital Beverages Global Inc Composiciones y métodos para el suministro selectivo en el tubo gastrointestinal
CN109310642B (zh) 2016-04-19 2021-07-20 费灵有限公司 美沙拉嗪的口服药物组合物
RU2738114C2 (ru) 2016-04-19 2020-12-08 Конарис Рисёрч Инститьют Аг Пероральные фармацевтические композиции никотинамида
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
TR201722852A2 (tr) * 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
US4743248A (en) 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE69014513T2 (de) 1989-09-21 1995-05-24 American Cyanamid Co System des Typs "einmal täglich" zur gepulsten Minocyclinabgabe.
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
WO1992004472A1 (en) * 1990-09-07 1992-03-19 Oklahoma Medical Research Foundation Antigens associated with polymyositis and with dermatomyositis
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
AU694655B2 (en) * 1995-05-02 1998-07-23 Taisho Pharmaceutical Co., Ltd. Composition for oral administration
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
ATE380023T1 (de) 2007-12-15
AU5432401A (en) 2002-01-17
EP1172100B1 (en) 2007-12-05
JP2002080398A (ja) 2002-03-19
EP1172100A1 (en) 2002-01-16
DE60131703D1 (de) 2008-01-17
AU776099B2 (en) 2004-08-26
US20020034541A1 (en) 2002-03-21
DE60131703T2 (de) 2008-11-20
IT1318625B1 (it) 2003-08-27
CA2352496A1 (en) 2002-01-14
US7022345B2 (en) 2006-04-04
ITMI20001603A1 (it) 2002-01-14

Similar Documents

Publication Publication Date Title
ITMI20001603A0 (it) Formulazioni farmaceutiche solide orali a rilascio multifasico ph-dipendente
ITMI991316A0 (it) Composizioni farmaceutiche orali a rilascio modificato di mesalazina
NO2015026I2 (no) panobinostat eller et farmasøytisk akseptabelt salt derav
CY2007031I1 (el) Συνθεση στοματικης δοσολογιας παρατεταμενης απελευθερωσης
NO20030713D0 (no) Oral faststoffdose vaksine
ATE355271T1 (de) Pharmazeutische zusammensetzung
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
HUP0204409A3 (en) Sustained release ranolazine pharmaceutical compositions
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
EP1383376A4 (en) PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20030418D0 (no) Nytt farmasöytisk preparat
ITMI20010748A0 (it) Composizioni farmaceutiche
MA27487A1 (fr) Preparation solide
HUP0301949A3 (en) Compounds with a sulfonamide group and pharmaceutical compositions containing these compounds
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20015670L (no) Forbedrede farmasöytiske formuleringer
NO20026123L (no) Farmasöytiske sammensetninger
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
ITMI20000440A0 (it) Forme solide orali a rilascio controllato contenenti mesalazina come principio attivo
NO20031095D0 (no) Farmasöytiske sammensetninger
FI5176U1 (fi) Sitalopraamia sisältävä farmaseuttinen koostumus
PT1272499E (pt) Composicoes farmaceuticas contendo oligossacaridos e a sua preparacao
HUP0401587A3 (en) A new extended release oral dosage form